ide

Indian pharma & biotech cos confident of new US President Trump's support to Indian pharma

Indian pharma and biotech companies are confident that under the new US President Donald Trump, its strengths in high quality generics manufacture and export will continue to command respect. This view is




ide

DoP releases operational guidelines for Strengthening of Medical Device Industry scheme

The Department of Pharmaceuticals (DoP) has released the operational guidelines for the newly announced central sector scheme for Strengthening of Medical Device Industry (SMDI), aiming at providing




ide

What to consider with 3D printing and plastics prototyping

Robert Musselle, customer engineering manager EMEA at Protolabs shares what you need to consider with 3D printing and plastics prototyping.




ide

LFH Regulatory to attend MEDICA to provide guidance on navigating markets

Regulatory experts LFH Regulatory have announced their attendance at MEDICA 2024 to provide insights and support to healthcare innovators facing the complexities of the UK and EU markets.




ide

In 2024’s Record-Hottest Year, U.S. Voters Will Decide Climate’s Path Forward

Global temperatures through September point to 2024 besting 2023 as the hottest year on record. How many future years set records depends in part on the outcome of the 2024 U.S. presidential election




ide

The Universe in 100 Colors Provides a Stunning Tour through Science

A science photo book probes the colors we can see—and even “forbidden” colors we can’t




ide

Misinformation Really Does Spread like a Virus, Epidemiology Shows

“Going viral” appears to be more than just a catchphrase when it comes to the rampant spread of misinformation




ide

Consciousness Might Hide in Our Brain’s Electric Fields

A mysterious electromagnetic mechanism may be more important than the firing of neurons in our brain to explain our awareness




ide

Glasses Provide Audible Prompts for Blind Wearers

A team at the University of Technology Sydney has developed an assistive technology for blind people and those with low vision. The system consists of glasses that can view their surroundings through an on-board camera, appraise the objects nearby using computer vision technology, and then play a sound that provides a cue for the wearer […]




ide

Drug Channels News Roundup, September 2024: Inside JNJ’s Gross-to-Net Bubble, Optum Rx’s Private Label Biosimilars, Where Biosimilars Boom, Accumulators vs. Patients, and Steve Collis Retires

Autumn is here! Curl up with your favorite pumpkin-spiced blog and savor these acorns that we’ve squirrelled away for you:
  • Johnson & Johnson Innovative Medicines gives a peek inside its $43 billion gross-to-net bubble
  • Optum Rx joins the private label biosimilar bandwagon
  • Biosimilars boom for provider-administered drugs
  • Fresh evidence of how copay accumulators hurt patients
Plus, words of wisdom from Cencora's soon-to-be-former CEO Steve Collis.

P.S. Join my more than 58,000 LinkedIn followers for daily links to neat stuff along with thoughtful and provocative commentary from the DCI community.

There’s still time to request an invite to the inaugural Drug Channels Leadership Forum. Attendance will be highly limited. We have already begun extending invitations, so apply now to be considered. Click here to view the full agenda.

Read more »
       




ide

NEW: The Drug Channels 2025 Video Webinar Series

Drug Channel Institute is pleased to announce The Drug Channels 2025 Video Webinar Series.

Join Dr. Adam J. Fein for three live video webinars during 2025. These live, interactive events will be broadcast via Zoom from the Drug Channels Video studio in beautiful downtown Philadelphia.

During these events, Dr. Fein will address the latest issues confronting the U.S. drug channel. Topics will be determined based on what’s happening—trends, policy changes, company announcements, and more. He’ll share DCI’s latest market data to help you stay on top of new developments. You will be able to use these events as both a capstone of your current learning and a touchpoint for the future.

The three events are scheduled for 12:00 p.m. to 1:30 p.m. ET on the following dates:
  • April 4, 2025
  • June 20, 2025
  • December 12, 2025 (Drug Channels Outlook 2026)
For 2025, we are offering a Corporate Pricing option that will allow larger organizations to register hundreds of colleagues for one fixed price. Please contact Paula Fein (paula@drugchannels.net) for details.

Read on for full details on pricing, including substantial discounts for multiple sites.

P.S. If you're not familiar with our webinars, click here to watch brief excerpts from our video webinars.
Read more »
       




ide

No More Delays: Accelerating Therapy Starts by Embedding Hub Services in Provider Workflows

Today’s guest post comes from Shabbir Ahmed, Chief Commercial Officer at CareMetx.

Shabbir explains the barriers that providers face when dealing with branded portals for multiple products. He then maintains that patients can access new therapies more quickly when the manufacturer relies on a brand-agnostic hub connected to a large network of providers and integrated with the systems those providers use daily.

To learn more, download CareMetx’s new 2024 Patient Services ReportRevealing Manufacturer Priorities: Patients Naturally Take Center Stage.

Read on for Shabbir’s insights.
Read more »
       




ide

Drug Channels News Roundup, October 2024: Humira Price War Update, PA vs. Providers, IRA vs. Physicians, My AI Podcast, New DCI Jobs, and Dr. G on Copayments

Eeek! It's time for Drug Channels’ Halloween roundup of terrifying tales to share with your ghoulish fiends. This month’s tricks and treats:
  • Spooky! Blue Shield of California frightens away the gross-to-net bubble with its Humira biosimilar strategy
  • Vampiric! Prior authorization sinks its fangs into providers’ time
  • Wicked! How the IRA will put a stake through specialty physician practices
  • Eerie! Google’s monstrous AI podcasts leave me petrified
  • Zoinks! Join the vampire hunters at Drug Channels Institute
Plus, Dr. Glaucomflecken tells us a frightening tale of copayments.

P.S. Stretch out your arms and join the ever-growing zombie horde who shamble after me on LinkedIn. You’ll find my ghostly rantings along with commentary from the undead hordes in the DCI community.
Read more »
       




ide

Drug Channels Outlook 2025 (NEW Live Video Webinar)

Adam J. Fein, Ph.D., president of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for DCI’s new live video webinar:


This event will be broadcast live on
Friday, December 13, 2024,
from 12:00 p.m. to 1:30 p.m. ET

This post describes the event and explains how to purchase a registration. (Or, just click here to order.) The webinar will be broadcast from the Drug Channels studio in beautiful downtown Philadelphia.

This event is part of The Drug Channels 2024 Video Webinar Series. (Please note that our December 2024 webinar is *not* included with next year’s 2025 Video Webinar Series.)

WHAT YOU WILL LEARN

Join Dr. Fein as he helps you and your team get ready for 2025 by outlining key issues and uncertainties that will surely affect your planning. This event can be both a capstone of your annual learning and a touchpoint for the future. DCI’s Outlook webinars have proven to be reliable and informative guides to crucial aspects of the ever-evolving healthcare industry.

During the event, Dr. Fein will share his latest thinking and projections on a wide range of topics, including:
  • Latest predictions for the Inflation Reduction Act
  • Expectations for the Medicare Part D market in 2025 and beyond
  • Update on 340B Drug Pricing Program’s controversies
  • Impact of the new Trump administration and Congress on the drug channel
  • Vertical integration and consolidation trends—and prospects for dis-integration and de-consolidation
  • The state of biosimilar markets
  • What’s next for PBMs’ private label products and GPOs
  • Retail pharmacy’s future
  • Prospects for direct-to-patient channels
  • What’s ahead for discount cards and cash-pay pharmacies
  • The outlook for state and federal legislation on PBMs and the drug channel
  • Gross-to-net bubble developments
  • And much more!
PLUS: During the webinar, Dr. Fein will give participants an opportunity to unmute themselves and ask live questions. The webinar will last at least 90 minutes to accommodate audience questions.

As always, Dr. Fein will clearly distinguish his opinions and interpretations from the objective facts and data. He will draw from exclusive information found in DCI's economic reports .

Read on for full details on pricing and registration.
Read more »
       




ide

FDA Funding: Agency Mission “At Risk”, Says Alliance President

FDA’s mission is “at risk” because of inadequate funding. So says Alliance for a Stronger FDA President Diane Dorman, testifying before the FDA Science Board. Her remarks come 5 years after the Science Board made a similar declaration, concluding that decades of underfunding had left FDA without the resources to fulfill its mandate and make science-based decisions. Congress responded with more monies for the agency, but since then the FDA’s workload has increased even faster. The current threat to FDA comes from two sources: four major new laws to implement since 2009; and changes in the environment in which FDA operates, notably acceleration of globalization and increasing scientific complexity. Ms. Dorman’s remarks are reprinted below. If you care about FDA, FDA Matters urges you to read her testimony, go to the Alliance’s site (www.StrengthenFDA.org) and join.




ide

Semaglutide effective for weight loss in non-diabetic adults, research suggests

The type 2 diabetes mellitus drug semaglutide is effective for weight loss in non-diabetic overweight or obese adults, when taken alongside a reduced-calorie diet and exercise, researchers have found.




ide

UK universities and NHS trusts that flout the rules on clinical trials identified in report to Parliament

An AllTrials report for the House of Commons Science and Technology Select Committee this week has found that 33 NHS trust sponsors and six UK universities are reporting none of their clinical trial results, while others have gone from 0% to 100% following an announcement from the Select Committee in January that universities and NHS […]




ide

AllTrials guide to asking academic institutions about missing results

When university and hospital trusts were called to the UK parliament last year to answer questions on why they were not following the rules on reporting results, we saw how effective the questioning from politicians was. Those of you who watched the parliamentary session saw the pressure the university representatives were put under. Because the politicians asked […]




ide

Nama-Nama Provider Slot Online Terbaik 2024

Industri slot online terus mekar dan mengukir epik baru dalam dunia judi online. Tahun 2024 menjadi saksi bagi loncatan tinggi dalam inovasi dan hiburan, terutama dari para provider terkemuka yang…

The post Nama-Nama Provider Slot Online Terbaik 2024 appeared first on Biosimilarnews.




ide

Provider Judi Slot Gacor Online Terbaik serta Populer di Tahun 2024

Seolah-olah melintasi portal waktu, kita memasuki tahun 2024 dengan deretan provider judi slot online yang tidak hanya menemani, tetapi juga menggoda imajinasi. Setiap klik, setiap putaran gulungan, membuka lembaran baru…

The post Provider Judi Slot Gacor Online Terbaik serta Populer di Tahun 2024 appeared first on Biosimilarnews.




ide

CVS Health Exec: Payers Need to Stop Making Behavioral Health Providers Jump Through Hoops In Order to Participate in Value-Based Care

Value-based care contracting is especially difficult for behavioral health providers, Taft Parsons III, chief psychiatric officer at CVS Health/Aetna, pointed out during a conference this week.

The post CVS Health Exec: Payers Need to Stop Making Behavioral Health Providers Jump Through Hoops In Order to Participate in Value-Based Care appeared first on MedCity News.




ide

There’s an Opportunity for More Providers to Partner with the 988 Lifeline, Execs Say

Two executives at behavioral health care companies discussed why it’s important for provider organizations to partner with the 988 Suicide & Crisis Lifeline during a panel at the Behavioral Health Tech conference.

The post There’s an Opportunity for More Providers to Partner with the 988 Lifeline, Execs Say appeared first on MedCity News.




ide

Inside Providence’s Health Equity & Medicaid Strategy

Whitney Haggerson — vice president of health equity and Medicaid at Providence — discussed the significance of her role, as well as how her health system is working to give all employees, regardless of title, the skills needed to help reduce health inequities.

The post Inside Providence’s Health Equity & Medicaid Strategy appeared first on MedCity News.




ide

Biden Administration Should Prioritize Fight Against Superbugs

The Pew Charitable Trusts joined dozens of research, health care, and nonprofit stakeholders in urging President-elect Joe Biden to prioritize and strengthen the national response to antibiotic resistance.




ide

Primary Care Providers Can Help Steer People to Opioid Addiction Treatment

The United States is grappling with two severe health crises: the COVID-19 pandemic and an opioid epidemic that appears to be worsening as more people deal with stress and isolation as they face increased barriers to medical care. Preliminary numbers for 2020 show that overdose deaths were outpacing the record-setting number of more than 71,000 fatalities in 2019.




ide

En Banc: Federal Circuit Provides Guidance on Application of On-Sale Bar to Contract Manufacturers

Pharmaceutical and biotech companies breathed a sigh of relief Monday when the Federal Circuit unanimously ruled in a precedential opinion that the mere sale of manufacturing services to create embodiments of a patented product is not a “commercial sale” of the invention that triggers the on-sale bar of 35 U.S.C. § 102(b) (pre-AIA).[1]  The en banc opinion...… Continue Reading





ide

China unveils first diagnosis guidelines to battle escalating obesity crisis

HONG KONG — China's National Health Commission (NHC) published its first set of guidelines to standardise the diagnosis and treatment of obesity, with more than half of China's adults already overweight and obese, and the rate expected to keep rising.  The guidelines, made public on October 17, come as China experiences an upward morbidity trend of its overweight and obese population. The rate of overweight or obese people could reach 65.3 per cent by 2030, the NHC said.   "Obesity has become a major public health issue in China, ranking as the sixth leading risk factor for death and disability in the country," the guidelines said. China is facing a twin challenge that feeds its weight problem: In a modernising economy underpinned by technological innovation, more jobs have become static or desk-bound, while a prolonged slowdown in growth is forcing people to adopt cheaper, unhealthy diets.




ide

Trump's Day One: Deportations, border wall, scrapping Biden humanitarian programs

WASHINGTON — Donald Trump is expected to take a slew of executive actions on his first day as president to ramp up immigration enforcement and roll back signature Biden legal entry programs, a sweeping effort that will be led by incoming "border czar" Tom Homan and other Republican immigration hardliners, three sources familiar with the matter told Reuters. The executive actions would give federal immigration officers more latitude to arrest people with no criminal records, surge troops to the US-Mexico border and restart construction of the border wall, the sources said. Homan, who served as acting director of US Immigration and Customs Enforcement from 2017-2018 under Trump, will bring a deep understanding of the US immigration system after a four-decade career that took him from a frontline Border Patrol agent to head of the agency that arrests and deports immigrants in the US illegally.




ide

Nowhere to Hide? Global Policing and the Politics of Extradition

U.S. power extends beyond the military and economic spheres to include policing. The United States has used its global policing power to capture terrorists, warlords, and drug kingpins. But extradition is not simply a bureaucratic tool. States’ geopolitical interests shape their willingness to cooperate with others in extraditing fugitives. 




ide

237503: The President's announcement on the way forward in Afghanistan and Pakistan

This cable contains information which we hope will be useful to you in engaging host governments, media, and the public after the President's address.




ide

U.S. confident of safety of nuclear weapons, despite al-Qaeda presence



  • The India Cables

ide

214563: NSA Jones' June 25 meeting with President Zardari

Zardari made repeated pleas for drones to be "put in Pakistan's hands" so that Pakistan would own the issue and drone attacks (including collateral damage) would not provoke anti-americanism.




ide

155753: Codel Feingold meets with President Musharraf

President Musharraf also asked the U.S. to put more pressure on India to negotiate over Kashmir, concluding that the time is ripe for resolution of the issue.




ide

185384: Menon says India to decide on information-sharing with Pakistan

Menon emphasized that India had been tough on Pakistan with regard to accountability, but restrained in its rhetoric and actions.




ide

190946: Interior Secretary provides terms of A.Q. Khan's modified detention

S.M. Zafar, Khan's prominent and highly respected lawyer, had pledged to the government that the meeting with the press would be Khan's "first and last" such encounter.




ide

Explained | How is the Congress president elected?

As leaders mull over who will head the party next, the Congress Working Committee announced that elections will be held on October 17.




ide

Pakistan raised Mujahideen and now they are terrorists, says Pakistan Interior Minister in National Assembly

The Pakistani Taliban on Monday claimed responsibility for the January 30 mosque attack in Peshawar which left 100 people dead and over 220 injured




ide

Allies: Twenty-Seven Bold Ideas to Reimagine the US-Colombia Relationship

This book is intended to advance the next phase of the U.S.-Colombia relationship. In a rapidly changing world, the following chapters present a roadmap for a new type of engagement that challenges our ambitions and extends the ties that bind our countries. 




ide

Former Colombian President Iván Duque Discusses Resurgent Left Wing in Latin America at Kennedy School Event

Former Colombian President Iván Duque discussed Latin America’s resurgent left wing and advocated for environmental action at the Harvard Kennedy School on Thursday afternoon.




ide

"Biden makes suprise visit to Ukraine before heading to Poland for invasion anniversary"

U.S. President Joe Biden spent five hours in the Ukrainian capital on Monday, meeting President Volodymyr Zelensky and even taking a stroll through the streets of Kyiv – despite the sound of air sirens – to visit The Wall of Remembrance, which displays portraits of the approximately 4,500 Ukrainian soldiers who have died since Russia annexed Crimea in 2014.

The trip was kept under a media blackout until a few hours after Biden’s arrival, with the president’s official schedule only saying he would fly in the evening to Warsaw for a planned visit. The New York Times reported, quoting an anonymous official source, that Biden arrived in Kyiv early this morning after making the same 10-hour long journey from Poland that every world leader visiting Ukraine since the start of the war has.




ide

Writing Policy Recommendations for Academic Journals: A Guide for the Perplexed

How can scholars write effective policy recommendations? Despite the potential importance of academic work to the policy debate, many scholars receive little training on why and how to make policy recommendations. To remedy this problem, here are steps to guide scholars as they begin developing policy recommendations for their articles. 




ide

Potential Fruits of the Biden-Putin Summit

The last time Joe Biden met Vladimir Putin, the two did not exactly hit it off. During the March 2011 meeting the-then vice president of the United States urged the then-prime minister of Russia not to return to the Kremlin, and then claimed to have reached unflattering conclusions about his Russian counterpart’s soul after the meeting was over. Putin too seems to have no love lost for Biden, even if he has been less blunt in showing it.




ide

6 Months On: Does the Biden-Putin Summit Get a Passing Grade?

One of the few things America’s Joe Biden and Russia’s Vladimir Putin had agreed upon prior to their first summit almost half a year ago was that they would not hold a joint press conference after their June 16 huddle at an 18th century villa in Geneva. The two presidents’ decision to talk to press separately came as no surprise, given how many major issues they publicly disagreed on at the time.




ide

Harvard Project — with the Salata Institute — Provides Support for Students to Attend COP-28

The Harvard Project on Climate Agreements collaborated with the Salata Institute on Climate and Sustainability at Harvard University to provide financial and logistical support for students to attend the Twenty-Eighth Conference of the Parties (COP-28) to the United Nations Framework Convention on Climate Change (UNFCCC). COP-28 will be held in Dubai, Nov. 30 – Dec. 12, 2023.




ide

HPCA Hosts COP 28 Side Event on the Challenges and Opportunities of Reducing Global Methane Emissions

The Harvard Project on Climate Agreements (HPCA) assembled a panel of leading academics and government officials to discuss strategies for achieving significant methane emissions reductions at relatively low costs at an official COP 28 Side Event last Wednesday (Dec. 6). The event, titled “Reducing Global Methane Emissions: Imperatives, Opportunities, and Challenges,” was moderated by HPCA Director Robert Stavins.




ide

Why Militaries Support Presidential Coups

If you want to understand why generals support a presidential power grab, then you need to understand the logic that motivates them. Why they leave the barracks — and what we must do to get them to stand down.  





ide

Trump wins US presidential election